News
Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...
Eli Lilly raised the price of its GLP-1, Zepbound, from about $125 to $165 and plans an additional hike next month that would almost double its price. In a note to clients Friday, Bank of America ...
Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these findings, a clear link has yet to be established, and much of the evidence remains ...
Uncover the truth about GLP-1 weight loss drugs like Ozempic and Mounjaro. Learn how they work, who benefits most, potential risks, and why experts say they can be game-changing tools for fighting ...
“From 2019 to 2024, the percentage of adult patients with a diagnosis of overweight or obesity increased 50.7 percent, and ...
A recent study aimed to assess evidence on the safety and complications of preoperative glucagon-like peptide-1 (GLP-1) ...
The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...
Doctors and many patients say GLP-1 drugs can help solve the growing problem of obesity. But some bristle at the thought that ...
Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.
THE price of Mounjaro is set to soar, The Sun revealed yesterday – leaving slimmers desperate and worried at how they will afford the ‘life-changing’ drug. With the price hike ...
A growing wave of lawsuits is targeting Novo Nordisk, the manufacturer of the widely used drugs Ozempic and Wegovy, following ...
Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results